The in vitro diagnostics (IVD) sector stands as a cornerstone of modern healthcare, empowering clinicians with the tools to detect diseases, monitor health conditions, and guide precise treatment decisions.
As healthcare evolves, the IVD market is poised for transformative growth. With the rising prevalence of chronic conditions such as diabetes and cardiovascular diseases, as well as ongoing threats from infectious diseases like COVID-19 and emerging variants, the demand for innovative diagnostic solutions has never been greater.
In Vitro Diagnostics Business Outlook is a bimonthly publication, delivering six issues annually, each dedicated to a different segment of the IVD industry. It provides exclusive insights and data, including:
Market Data and Forecasts: Detailed growth rates, market size, and market share to identify new opportunities.
Comprehensive Market View: Coverage of test categories and company profiles.
M&A Activities: Updates on mergers, acquisitions, partnerships, and collaborations.
Industry & Region Watch: Tailored strategies based on regional and industry-specific trends.
News Analysis: In-depth reporting on significant news and events, including exclusive information not readily available elsewhere.
Table of Contents
Volume 4, Issue 1 – Focus on Cardiac Biomarkers
Market Analysis: Cardiac Biomarker Testing
Overview of Cardiac Biomarkers
Market Outlook
Figure: Cardiac Marker Testing Market by End User, 2024-2029 ($ million) (Lab-based, POC-based)
Table: Cardiac Marker Diagnostic Sales by End User, 2024-2029 ($ million) (Lab-based, POC-based)
Figure: Cardiac Marker Testing Market by End User and Total Value Over Time, 2019-2029 ($ million) (Lab-based, PoC-based)
QIAGEN Receives FDA Clearance for Five-Target Syndromic Panel
Revvity Secures FDA Clearance for Free Testosterone Test
Spear Bio Secures FDA Breakthrough Device Designation
Roche Announces Clearance of First ISH Test B-cell Lymphoma
Roche Receives Additional FDA Clearance
Volume 4, Issue 2 – Focus on Infectious Disease Testing
Market Analysis: Infectious Disease Testing
Overview of Infectious Disease Testing
Market Outlook
Table 1: Global Infectious Disease Testing Market Revenue, by Segment, 2024-2029 ($ million) [Lab-based Immunoassays, Lab-based Molecular, Point-of-Care Tests]
Figure 1: Global Infectious Disease Testing Market, by Segment, 2019-2029 ($ million) [Lab-based Immunoassays, Lab-based Molecular, Point-of-Care Tests]
Figure 2: Global Infectious Disease Testing Market, Change in Market Performance by Segment, 2023-2024 [Blood Bank Screening, COVID-19, HAIs/Sepsis, Hepatitis, HIV, Respiratory (excl. COVID), Others]
Figure 3: Global Infectious Disease Testing Market, by Analyte Target, Distribution of Sales, 2024 [Blood Bank Screening, COVID-19, HAIs/Sepsis, Hepatitis, HIV, Respiratory (excl. COVID), Others]
Regional Market
Table 2: Infectious Disease Testing, Distribution by Global Region, 2024 [North America, Europe, Asia Pacific, RoW]
Company Briefs
Roche
Abbott
Danaher
Other Participants
Executive News Briefing
Briefings
Dxcover Limited Raises New Capital
Cubit Diagnostics Awarded NIH Funding
CARB-X Funds AstraDx’s Neonatal Sepsis Rapid Test
Freenome Raises Additional $254 Million
Renovaro Secures $15 Million in New Capital
Ataraxis AI Secures $20.4 Million in Funding
MSInsight Nabs €1.6 Million Seed Funding
C2N Diagnostics Receives $10 Million Investment
Financial Highlights: Guardant Health, Roche
Guardant Reports Strong Demand – Increasing Revenues +31% Over Previous Year
Figure 4: Guardant Health Test Volume, by Segment and Total, Quarterly Q1 2023 through Q4 2024 [Biopharmaceutical Customers, Clinical Customers]
Table 3: Guardant Health, by Group Business Revenue, FY 2023 vs FY 2024 ($ million) [Clinical Precision Oncology Testing, Development Services and Other]
Figure 5: Guardant Health, by Group Business, FY 2023 vs FY 2024 ($ million) [Clinical Precision Oncology Testing, Development Services and Other]
Figure 6: Guardant Health Revenue Performance, by Geographic Region, FY 2023 vs FY 2024 ($ million) [United States, International]
Roche Diagnostic Sales Grow 4% CER in 2024 – Supported by Demand for Immunodiagnostics, Pathology, and Molecular Solutions
Table 4: Roche, by Group Business, 2024 (CHF MN) [Diagnostic Division, Pharmaceutical Division]
